Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ark Genomic Revolution ETF
(NY:
ARKG
)
26.26
-0.48 (-1.80%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ark Genomic Revolution ETF
< Previous
1
2
3
4
5
6
7
8
9
Next >
A Leaky ARKK
January 04, 2022
In a year when everything skyrocketed to nauseating highs, Cathie’s momentum-obsessed investing style was a dud.
Via
Talk Markets
UiPath Stock Is Worth Believing in Here as Wood Holds Fast
December 30, 2021
Cathie Woods ARK Investment ETFs have loaded up on shares of UiPath despite the decline. PATH stock has plenty of upside from here.
Via
InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
December 22, 2021
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.
Via
Talk Markets
Cathie Wood Added To Stake In This Medical Technology Company As Its Shares Surged 6% On Friday
December 20, 2021
Cathie Wood’s Ark Investment Management on Friday bought 26,126 shares — estimated to be worth $163,026 — in Quantum-Si Inc (NASDAQ: QSI). Shares of the medical...
Via
Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
December 14, 2021
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...
Via
Talk Markets
Neck Cream Reversal
November 18, 2021
Cathie Wood's ARKG is down about 50% over the past 9 months.
Via
Talk Markets
Bionano Genomics Proves Not Everything Genetic is Gold
December 01, 2021
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.
Via
InvestorPlace
Cathie Wood Testing 'ARK On Steroids' As ARK Funds Struggle
November 24, 2021
Wood said ARK is testing a strategy to short stocks in the big benchmark indexes,
Via
Investor's Business Daily
Topics
Electric Vehicles
Exposures
Electric Vehicles
Don't Look Now, But Cathie Wood's Ark Is Taking On Water
November 24, 2021
Among the biggest losers over the last 48 hour tech stock volatility has been...well, everything in Cathie Wood's
Via
Talk Markets
Biotech Stocks are Due for a Rally
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Yes, Cathie Wood's $700,000 Bitcoin Price Prediction Is Legit
November 21, 2021
A Bitcoin price prediction of $700,000 - more than 10 times the recent price - would strike most people as delusional. But this eye-popping target doesn't come from a Bitcoin fan. It comes from Wall...
Via
Talk Markets
Tesla (TSLA) Not Enough To Lift ARK Innovation (ARKK)
October 27, 2021
An updated look at Cathie Wood’s ARK ETFs relative strength versus the S&P 500 SPY ETF.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
October 21, 2021
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage.
Via
Talk Markets
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
October 06, 2021
Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE:
Via
Benzinga
Mike Khouw Sees Unusual Options Activity In ARK Genomic Revolution ETF
September 29, 2021
On CNBC's "Options Action," Mike Khouw said ARK Genomic Revolution ETF (BATS: ARKG) was active on Tuesday as it traded six times its average daily put volume....
Via
Benzinga
Biotech Playbook Revisited As Technicals Weaken
September 27, 2021
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...
Via
Talk Markets
Look For The Q4 Biotech Bounce In Mid-Small Caps
September 17, 2021
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...
Via
Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
September 09, 2021
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Via
Talk Markets
3 Healthcare Stocks Cathie Wood Loves Right Now
September 03, 2021
Here's why the founder and CEO of ARK Invest set her sights on these three healthcare stocks.
Via
The Motley Fool
Healthcare Stocks Hit New Highs but Small Caps Lag
August 23, 2021
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field.
Via
Talk Markets
Cathie Wood's Ark Adds Another $29M To Palantir Stake After Q2 Earnings Beat, Buys DraftKings On Dip
August 15, 2021
Cathie Wood-led Ark Invest on Friday snapped up 1.156 million shares — estimated to be worth about $28.78 million — in...
Via
Benzinga
Topics
Earnings
Exposures
Financial
Palantir, Alibaba, Square, Twitter, DraftKings — Stocks Cathie Wood's Ark Bought Or Sold On Thursday
August 13, 2021
Cathie Wood-led Ark Invest on Thursday increased the exposure in Palantir Technologies Inc (NYSE...
Via
Benzinga
Teladoc's Earnings Had 1 Important Metric for Both Bulls and Bears
August 08, 2021
Which story do you believe?
Via
The Motley Fool
As Zymergen Crashes 76%, Cathie Wood Piles Up $2.5M Worth Of Shares
August 05, 2021
A bullish Ark Invest on Wednesday more than doubled its stake in Zymergen Inc (NASDAQ: ZY) after it plummeted due to the company’s “immaterial” revenue...
Via
Benzinga
Q2 Growth 'Nothing Short Of Virtuous': Economist
July 29, 2021
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic. What...
Via
Benzinga
Exposures
COVID-19
Cathie Wood Doubles Down On Teladoc, Spotify, Shopify As Stocks See Earnings-Related Dips
July 29, 2021
Cathie Wood-led Ark Investment Management on Wednesday piled up 713,842 shares, estimated to be worth about $108.37 million, in
Via
Benzinga
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll
July 15, 2021
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed...
Via
Benzinga
A Comprehensive Guide To Genomic ETFs
July 11, 2021
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...
Via
Talk Markets
Where Will ARK Genomic Revolution ETF Be in 5 Years?
July 10, 2021
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Via
The Motley Fool
Mid-Cap Biotech Picks: Seasonal Rally Underway
July 03, 2021
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.